BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition

Tyrosine kinase inhibitors (TKI) are widely used to treat patients with leukemia driven by BCR-ABL11 and other oncogenic tyrosine kinases2,3. Recent efforts focused on the development of more potent TKI that also inhibit mutant tyrosine kinases4,5. However, even effective TKI typically fail to eradi...

詳細記述

保存先:
書誌詳細
主要な著者: Duy, Cihangir, Hurtz, Christian, Shojaee, Seyedmehdi, Cerchietti, Leandro, Geng, Huimin, Swaminathan, Srividya, Klemm, Lars, Kweon, Soo-mi, Nahar, Rahul, Braig, Melanie, Park, Eugene, Kim, Yong-mi, Hofmann, Wolf-Karsten, Herzog, Sebastian, Jumaa, Hassan, Koeffler, H Phillip, Yu, J. Jessica, Heisterkamp, Nora, Graeber, Thomas G., Wu, Hong, Ye, B. Hilda, Melnick, Ari, Müschen, Markus
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3597744/
https://ncbi.nlm.nih.gov/pubmed/21593872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09883
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料